Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (539)	12/30/2002 11:32:43 AM
From: Jibacoa	Read Replies (1) \| Respond to of 7424

SUPG was up more than 15% earlier and it is still holding above the initial up-gap. It announced that it has filed an NDA for Orathecin,which had been given fast-track designation by the FDA last month. Orathecin is an oral chemotherapy treatment for patients with pancreatic Ca. who are resistant to other therapies. In spite of recent reported loss and cash/share of only $0.80 the insiders and institutions have been doing some buying lately. siliconinvestor.com Bernard